Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
- 33 Downloads
Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival.
A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6.1 million (72%) insured people in a 4-year observation period from January 2008 to December 2011. Only patients with first prescriptions of bDMARDs were included. All patients with diagnoses other than RA were excluded.
A total of 2906 first prescriptions of bDMARDs were included in the present analysis and 19.35% of RA patients were on bDMARDs in Austria taking into account a prevalence of RA of 0.5%. Tocilizumab showed the longest drug survival after 1 year (73.2%), followed by abatacept which had the longest drug survival after 2 (68.2%) and 3 years (65.2%). The most frequent second bDMARDs switched to were adalimumab (n = 109, 26%), tocilizumab (n = 83, 20%) and etanercept (n = 82, 20%) and 37% of biological DMARDs were prescribed as monotherapy (ranging from 33% with infliximab to 46% with tocilizumab).
Our analysis is based on the largest health care database available in Austria. Tocilizumab and abatacept showed the longest drug survival. Adalimumab, tocilizumab and etanercept were the most frequent DMARDs switched to. Of interest was the high number of bDMARD monotherapies.
KeywordsRheumatology Arthritis Epidemiology Biological DMARDs Drug survival
We thank the Austrian health insurance funds for provision of the data: BGKK, BVA, KGKK, NÖGKK, StGKK, SVA, SVB, VGKK, and WGKK.
Conflict of interest
T.A. Stamm, B. Reichardt, J. Zwerina, V. Ritschl, and V. Nell-Duxneuner declare that they have no competing interests.
- 10.Bundesgesetzblatt für die Republik Österreich. 473. Verordnung. 2004. http://vlex.at/vid/kontroll-heilmittel-nachfolgenden-versch-reibung-41330896 (Verordnung vom 10. Dezember 2004).Google Scholar
- 13.Cox D. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.Google Scholar
- 14.Fox JS, Weisberg HS. Cox proportinal-hazards regression for survival data in R. 2011.Google Scholar
- 19.British Society for Rheumatology Biologics Register, Kihara M, Davies R, Kearsley-Fleet L, et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol. 2017;36(2):241–50.CrossRefGoogle Scholar
- 25.Torrente-Segarra V, Acosta Pereira A, Morla R, et al. VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist. Reumatol Clin. 2016;12:319–22.CrossRefPubMedGoogle Scholar
- 26.Kaneko Y, Atsumi T, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75:1917–23.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Lee EB, Fleischmann RM, Hall S, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-nave patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:S1049.Google Scholar
- 33.Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.CrossRefPubMedGoogle Scholar
- 34.Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.CrossRefPubMedGoogle Scholar
- 39.Pincus T, Sokka T, Cutolo M. The past versus the present, 1980–2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015;22(1–2):89–103.CrossRefPubMedGoogle Scholar